

Press Release

Steffen Rinas
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-6698
F +49 6172 608-2294
steffen.rinas@fresenius.com
www.fresenius.com

November 22, 2021

Fresenius Helios acquires oncological center and ophthalmic clinic in Colombia

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed agreements to acquire Centro Oncológico de Antioquia (COA) and Clínica Clofán, further expanding the company's presence in Colombia. The clinics, located in Colombia's second largest city Medellín, will become part of Quirónsalud's existing healthcare network in the country, which already comprises six hospitals and ten diagnostic centers.

COA is specialized in the diagnosis and treatment of cancer. It has 75 beds, four operating rooms, and specialized centers for nuclear medicine, radiotherapy and bone marrow transplants. Clínica Clofán is the second largest ophthalmic center in the city, with ten operating rooms and further dedicated facilities for treating even severe ophthalmic diseases and performing complex procedures.

Both clinics offer state-of-the-art medical standards and technology to their patients and are regarded as leading medical facilities with highly renowned physicians. Together they generate sales of around €30 million.

The acquisition is another important step in strengthening Fresenius Helios' presence in the growing and consolidating healthcare services markets in Latin America.

The transaction is expected to close in the first quarter of 2022, pending anti-trust clearance of the Colombian authorities. Fresenius Helios expects the acquisition to be accretive to Fresenius' Group net income¹ already in fiscal year 2022.

#

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2020, Group sales were €36.3 billion. On September 30, 2021, the Fresenius Group had 314,852 employees worldwide.

For more information visit the Company's website at www.fresenius.com.
Follow us on social media: www.fresenius.com/socialmedia

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Sebastian Biedenkopf, Dr. Francesco De Meo, Rachel Empey, Rice Powell, Michael Sen, Dr. Ernst Wastler
Chairman of the Supervisory Board: Wolfgang Kirsch

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA